Feedback
Settings

Settings

Goto Application

1. WO2022165056 - TREATING CANCER IN PATIENT WITH PTEN INACTIVATING MUTATION

Submit observation
PermaLink
Publication Number WO/2022/165056
Publication Date 04.08.2022
International Application No. PCT/US2022/014125
International Filing Date 27.01.2022
IPC
A61K 31/519 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
A61K 31/5365 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
535having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
5365ortho- or peri-condensed with heterocyclic ring systems
C07D 498/04 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
498Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
A61P 35/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
CPC
A61K 31/5365
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
535having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
5365ortho- or peri-condensed with heterocyclic ring systems
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07D 498/14
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
498Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
12in which the condensed system contains three hetero rings
14Ortho-condensed systems
Applicants
  • TAIHO PHARMACEUTICAL CO., LTD. [JP]/[JP]
  • BENHADJI, Karim [FR]/[US]
Inventors
  • BENHADJI, Karim
  • TAKAHASHI, Osamu
Agents
  • ONOE, Yuki
  • KELLY, Richard
  • MASON, J. Derek
Priority Data
63/144,15301.02.2021US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) TREATING CANCER IN PATIENT WITH PTEN INACTIVATING MUTATION
(FR) TRAITEMENT DU CANCER CHEZ UN PATIENT ATTEINT D'UNE MUTATION D'INACTIVATION DE PTEN
Abstract
(EN) A method of treating a subject with a cancerous tumor exhibiting an inactivating mutation in the PTEN gene including administering to the subject trans-3-amino-1-methyl-3-(4-(3-phenyl-5H-imidazo[1,2-c]pyrido [3,4-e][1,3]oxazin-2-yl)phenylcyclobutanol or a pharmaceutically acceptable salt thereof.
(FR) L'invention concerne une méthode de traitement d'un sujet atteint d'une tumeur cancéreuse présentant une mutation d'inactivation dans le gène PTEN, qui consiste à administrer au sujet du trans-3-amino-1-méthyl-3-(4-(3-phényl-5 H-imidazo[1,2-c]pyrido [3,4-e][1,3] oxazin-2-yl) phénylcyclobutanol ou un sel pharmaceutiquement acceptable de celui-ci.
Latest bibliographic data on file with the International Bureau
# -